Human immunodeficiency virus type 1 antigens (Gag, Pol, Env) (HIV-1 antigens)

HIV-1 antigens expressed by MVA62B represent a specific set of viral proteins—typically Gag, Pol, and Env—derived from clade B strains of the Human Immunodeficiency Virus type 1 (NIH, 2010). These antigens are encoded within the genome of the Modified Vaccinia Ankara (MVA) vector, a replication-deficient poxvirus used as a vaccine delivery platform (Goepfert et al., 2011). Upon administration, the vector enters host cells and expresses these HIV-1 proteins, which are then processed and presented to the immune system via MHC class I and II molecules (HVTN, 2014). This process is designed to elicit robust HIV-specific cellular immune responses, particularly CD8+ cytotoxic T lymphocytes, and humoral responses involving neutralizing antibodies (PubMed: 21411740). The primary therapeutic goal is to prevent HIV infection or control viral replication in infected individuals by training the immune system to recognize these critical viral components (NIAID, 2012). MVA62B has been extensively studied in clinical trials, such as HVTN 065, often as a boost following a DNA vaccine prime to evaluate its safety and immunogenicity (ClinicalTrials.gov: NCT00428337).

Other names

HIV-1 Gag-Pol-EnvMVA62B-expressed antigensRecombinant MVA-HIV antigensMVA-B antigensHIV-1 clade B antigens

Induction of HIV-specific cellular and humoral immune responses through intracellular antigen expression and presentation via MHC pathways (Goepfert et al., 2014).